SCHEMBL1428200

SCHEMBL1428200

COC1CCN(Cc2ccc(Br)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ LTA4H P09960 1/20 0.52
▸ OPRM1 P35372 3/20 0.49
▸ OPRK1 P41145 1/20 0.49
▸ CARM1 Q86X55 1/20 0.49
▸ PRMT6 Q96LA8 1/20 0.49
▸ HRH3 Q9Y5N1 1/20 0.49
▸ SIGMAR1 Q99720 1/20 0.47
▸ ACHE P22303 2/20 0.46
▸ BCHE P06276 1/20 0.46
▸ BACE1 P56817 1/20 0.46
▸ CHRM2 P08172 1/20 0.45
▸ CHRM3 P20309 1/20 0.45
▸ CXCR3 P49682 1/20 0.45
▸ CCR5 P51681 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1240978 0.90 LTA4H (0.54) KDM4EALDH1A1LTA4HOPRM1CARM1
SCHEMBL1241949 0.90 LTA4H (0.54) KDM4EALDH1A1LTA4HOPRM1CARM1
SCHEMBL1240977 0.90 LTA4H (0.54) KDM4EALDH1A1LTA4HOPRM1CARM1
SCHEMBL12082512 0.85 ALDH1A1 (0.56) ALDH1A1LTA4HOPRM1OPRK1HRH3
SCHEMBL791901 0.85 MEN1 (0.55) KDM4EALDH1A1LTA4HOPRM1OPRK1
SCHEMBL3158273 0.83 LMNA (0.57) ALDH1A1LTA4HOPRM1OPRK1HRH3
SCHEMBL28375594 0.83 LTA4H (0.52) KDM4EALDH1A1LTA4HOPRM1OPRK1
SCHEMBL27891330 0.83 SIGMAR1 (0.63) LTA4HOPRM1SIGMAR1ACHEBACE1
SCHEMBL3866505 0.83 LTA4H (0.52) LTA4HOPRM1OPRK1HRH3SIGMAR1
SCHEMBL8096431 0.83 ACHE (0.66) LTA4HOPRM1OPRK1HRH3SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658656-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES Beone Medicines I GmbH (CH) 2025-12-10 — — EP disclosed
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-13 — — US disclosed
WO-2024160276-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEIGENE, LTD. (KY) 2024-08-08 — — WO disclosed
US-9216980-B2 Methods of use of diazacarbazoles for treating cancer GENENTECH, INC. (US) 2015-12-22 — — US disclosed
US-20150087630-A1 METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER GENENTECH, INC. (US) 2015-03-26 — — US disclosed
EP-2300475-B1 DIAZACARBAZOLES AND METHODS OF USE GENENTECH INC (US) 2014-11-05 — — EP disclosed
EP-2706059-A1 Diazacarbazoles and methods of use Genentech, Inc. (US) 2014-03-12 — — EP disclosed
US-20130261104-A1 METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER GENENTECH, INC. (US) 2013-10-03 — — US disclosed
US-8501765-B2 Diazacarbazoles and methods of use GENENTECH, INC. (US) 2013-08-06 — — US disclosed
US-20110118230-A1 DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. 2011-05-19 — — US disclosed
EP-2300475-A1 DIAZACARBAZOLES AND METHODS OF USE Genentech, Inc. (US) 2011-03-30 — — EP disclosed
WO-2009151598-A1 DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. (US) 2009-12-17 — — WO disclosed
EP-1943231-A1 (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-16 — — EP disclosed
US-20070111981-A1 New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds ROTH GERALD J 2007-05-17 — — US disclosed
WO-2007048802-A1 (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111981-A1 New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 KDM4E 1313/4885ALDH1A1 3960/4885LTA4H 1868/4885
US-20110118230-A1 DIAZACARBAZOLES AND METHODS OF USE CHEK1, CHEK2, BUB1B KDM4E 1462/4885ALDH1A1 570/4885LTA4H 3766/4885
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKA, DGKK KDM4E 2066/4885ALDH1A1 4075/4885LTA4H 1214/4885
US-20150087630-A1 METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER IDH3B, IDH3A, EGLN3 KDM4E 1064/4885ALDH1A1 220/4885LTA4H 3054/4885
US-20130261104-A1 METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER IDH3B, IDH3A, EGLN3 KDM4E 1064/4885ALDH1A1 220/4885LTA4H 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback